Stockscreener 앱 받기
0.7545
11.45%
0.0775
시간 외 거래:
.75
-0.0045
-0.60%
전일 마감가:
$0.677
열려 있는:
$0.6755
하루 거래량:
3.55M
Relative Volume:
0.50
시가총액:
$46.77M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-0.9551
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+13.05%
1개월 성능:
+28.21%
6개월 성능:
+18.82%
1년 성능:
+29.04%
1일 변동 폭
$0.6755
$0.855
1주일 범위
$0.6012
$0.855
52주 변동 폭
$0.2223
$1.29
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2403 SIDNEY STREET, PITTSBURGH
CGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7545 | 44.08M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c) - TipRanks
Cognition Therapeutics Reports Q2 2025 Results, Highlights Clinical Progress - AInvest
Cognition Therapeutics: Pivotal Alzheimer's Milestones and Strategic Pathways to Value Creation in 2025 - AInvest
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan
Published on: 2025-08-05 16:54:31 - beatles.ru
Top Risks to Consider Before Buying Cognition Therapeutics Inc. StockWeekly Chart Analysis With Entry Advice Provided - metal.it
Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News
What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News
What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News
Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News
How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News
What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News
What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com
Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - The Globe and Mail
Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News
What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance
Published on: 2025-07-29 20:05:06 - metal.it
Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times
How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it
Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire
Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan
Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest
What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):